

Notice of Allowability

Application No.

10/698,388

Applicant(s)

THOMAS ET AL.

Examiner

Art Unit

Sudhaker B. Patel, D.Sc.Tech.

1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 11/3/03.
2. ☒ The allowed claim(s) is/are 17-22.
3. ☐ The drawings filed on _____ are accepted by the Examiner.
4. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☒ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☒ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☒ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date 11/3/03
4. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☐ Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. ☐ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.

REASONS FOR ALLOWANCE

1. The following is an examiner's statement of reasons for allowance:

2. Applicants' communication paper dated 11/3/03 is acknowledged. Applicants have cancelled claims 1-16 and presented claims 17-22. Therefore, the claims under consideration are the claims 17-22 which are renumbered as claims 1-6 respectively.

3. The instant claims are related to method of use claims for the compounds already allowed. See the parent U.S. Application Sr. No. 10080716, filed 2/25/02).

4. The closest prior art reference of record (see the parent application as recited above) Rewcastle et al (J. Med. Chem. 38/18,3482-7(1995) teaches making of 7-amino-4- [(phenylmethyl) amino]- and 4-(phenylamino) quinazolines and related compounds as potent binding site inhibitors of tyrosine kinase domain of epidermal growth factor receptor.

The reference does not indicate or suggest arriving at the instant invention wherein 7-amino group of the quinazoline is further modified by R4 variable, and X1 of -X1-R4 can be (further in addition to-NR11-R4), CH2, S/SO/SO2, -NR7-CO-, -CONR8-, SO2NR9-, and -NR10SO2-.

5. The other prior art reference of record Baker et al (EP 566226, also cited as U.S.P. 5457105) teaches quinazoline derivatives wherein ref. R1 is not = instant -X1-R4 in the 7-position, and R4-X1- can not be H or methoxy group(s).

This reference also does not indicate or suggest arriving at the instant invention.

6. The prior art of record ref. Klohs et al(Chemical Abstract DN 132: 160709, also cited as Curr. Opin. Biotechnol. 10/6,544-549 (1999) does not qualify as a ref. because its publication date is 6/1999 whereas the instant application has a priority dated 9/25/1996.

7. Therefore the instant invention is deemed to be novel and patentably distinct.

8. The IDS papers submitted on 11/3/03 has been considered by examiner, and a signed copy of the PTO Form 1449 is enclosed with this communication for applicants' records.

9. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sudhaker B. Patel, D.Sc.Tech. whose telephone number is (571) 272-0671.

The examiner can normally be reached on 6:30 to 5:00 pm (Monday-Thursday). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Mukund J. Shah can be reached on (571) 272 0674 or Sr. Examiner Mr. Richard Raymond at (571) 272 0673 or Mr. James O. Wilson at (571) 272-0661.

Art Unit: 1624


The fax phone numbers for the organization where this application or proceeding is assigned are 703 308 4556 for regular communications and 703 308 4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308 1235. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system.

Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Sudhaker B. Patel, D.Sc. Tech.
September 10, 2004.



RICHARD L. RAYMOND
PRIMARY EXAMINER
ART UNIT 1624

MUKUND SHAH
SUPERVISORY PATENT
EXAMINER
ART UNIT 1624/1623